NEW YORK: Teva Pharmaceutical Industries Ltd said it settled a patent lawsuit with Pfizer Inc, allowing the Israeli drugmaker to launch a generic version of Pfizer’s blockbuster painkiller Celebrex in December.

In March, a US court invalidated a patent covering Celebrex, giving Pfizer’s rivals a chance to sell cheaper versions. Pfizer had said it would appeal the ruling.

The drug, which is used to treat arthritis pain and inflammation, generated about $2.92 billion in sales in 2013, according to Pfizer’s annual regulatory filing.

Teva, which is the world’s largest generic drugmaker, said it believed it was the first to file for an approval of a generic of three dose strengths of Celebrex.

Pfizer said on Thursday it would continue to defend the patent, which the US Patent and Trademark Office granted in March, extending its marketing exclusivity until Dec. 2, 2015.

The company sued several drugmakers, including Mylan Inc and Actavis Inc, which are also seeking US regulatory approval to sell their generic versions of Celebrex.

Opinion

Editorial

Judiciary’s SOS
Updated 28 Mar, 2024

Judiciary’s SOS

The ball is now in CJP Isa’s court, and he will feel pressure to take action.
Data protection
28 Mar, 2024

Data protection

WHAT do we want? Data protection laws. When do we want them? Immediately. Without delay, if we are to prevent ...
Selling humans
28 Mar, 2024

Selling humans

HUMAN traders feed off economic distress; they peddle promises of a better life to the impoverished who, mired in...
New terror wave
Updated 27 Mar, 2024

New terror wave

The time has come for decisive government action against militancy.
Development costs
27 Mar, 2024

Development costs

A HEFTY escalation of 30pc in the cost of ongoing federal development schemes is one of the many decisions where the...
Aitchison controversy
Updated 27 Mar, 2024

Aitchison controversy

It is hoped that higher authorities realise that politics and nepotism have no place in schools.